# A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Source: https://onco.cc/trials/nct06833073/  
OnCo record `nct06833073` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Intismeran autogene in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) is a phase 2 interventional study registered as NCT06833073 by Merck Sharp & Dohme LLC, with 308 participants planned, started 2025-03-11 and due to reach its primary completion in 2031-09-03. Interventions recorded: Intismeran autogene and BCG.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06833073
- Phase: 2
- Setting: A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 308

## Sources

- ClinicalTrials.gov NCT06833073: https://clinicaltrials.gov/study/NCT06833073

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Intismeran autogene](https://onco.cc/drugs/intismeran-autogene/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06833073.json